Literature DB >> 27396638

Adverse event development in clinical oncology trials.

Claudia Schmoor1, Ralf Bender2, Jan Beyersmann3, Meinhard Kieser4, Martin Schumacher5.   

Abstract

Mesh：

Year:  2016        PMID： 27396638     DOI： 10.1016/S1470-2045(16)30223-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Limitations of the incidence density ratio as approximation of the hazard ratio.

Authors:  Ralf Bender; Lars Beckmann
Journal:  Trials       Date:  2019-08-08       Impact factor: 2.279

2.  Marginal hazard ratio estimates in joint frailty models for heart failure trials.

Authors:  Gerrit Toenges; Antje Jahn-Eimermacher
Journal:  Biom J       Date:  2019-06-17       Impact factor: 2.207

3.  Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.

Authors:  Josephine A Adattini; Annette S Gross; Nicole Wong Doo; Andrew J McLachlan
Journal:  Pharmacol Res Perspect       Date:  2022-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.